Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Long-Term Outcome and Efficacy of Pr1/Bcr-Abl Multipeptides Vaccination in Chronic Myeloid Leukemia: Results of a 7-Year Longitudinal Investigation

Summary: New study shows promising results in chronic myeloid leukemia with a combination of PR1/BCR-ABL peptide vaccines and Imatinib, enhancing long-term response in patients. #LeukemiaResearch #Immunotherapy

Ghaffari SH1 ; Osfouri E1 ; Ahmadvand M1 ; Bashash D2 ; Ghaffari P1 ; Niavarani A3 ; Hossaini E1 ; Yaghmaie M1 ; Koohi R1 ; Ghashghaie A1 ; Pourbagherisigaroodi A4 ; Mousavi SA1 ; Alimoghaddam K1 ; Ghavamzadeh A5, 6
Authors

Source: Iranian Journal of Blood and Cancer Published:2022

Abstract

Background: Although Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML), not all patients reach complete remission and a considerable proportion of the patients develop resistance to Imatinib. Material and Methods: In an attempt to increase the tail on the survival curve, we conducted a Phase I/II study of PR1/BCR-ABL multipeptides vaccination trial in CML patients with at least 15 months of Imatinib treatment and 5 months of persistent molecular residual disease. Results: One month after the completion of the vaccinations, 4 patients nearly developed a 1-log fall in their BCR-ABL transcript level, with 4 patients achieving a major molecular response (MMR). Nine patients were followed for more than a period of 7 years. The vaccinations were associated with a MMR in five patients and a complete molecular response (CMR) in one patient. The removal of Imatinib in two patients who achieved MMR after the vaccinations led to a resurgence of the leukemia population and relapse. Conclusion: Our study suggests that a combination of immunotherapy with Imatinib targeted therapy keeps the leukemia population under control, improving the long-lasting clinical and molecular response of CML patients, for at least 7 years. © 2022, Iranian Pediatric Hematology and Oncology Society. All rights reserved.
Other Related Docs
4. A Single Center Study of Prescribing and Treatment Outcomes of Patients With Chronic Myeloid Leukemia, International Journal of Hematology-Oncology and Stem Cell Research (2020)
6. Imatinib Efficacy, Safety and Resistance in Iranian Patients With Chronic Myeloid Leukemia: A Review of Literature, International Journal of Hematology-Oncology and Stem Cell Research (2021)
12. Immunotherapy in Aml: A Brief Review on Emerging Strategies, Clinical and Translational Oncology (2021)
16. High Prevalence of Vitamin D Deficiency in Newly Diagnosed Acute Myeloid Leukemia Patients and Its Adverse Outcome, International Journal of Hematology-Oncology and Stem Cell Research (2017)
20. Immunotherapy in Bladder and Renal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)